Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
HRAS Q61L PLX7904 skin squamous cell carcinoma no benefit detail...
MAP2K1 E203K PIK3CA amp Metformin + Trametinib skin squamous cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02324608 Phase I Cetuximab Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer Completed USA 0
NCT02449681 Phase II TH-4000 Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS Terminated USA | AUS 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT02760498 Phase II Cemiplimab Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma Completed USA | ITA | GRC | FRA | ESP | DEU | BRA | AUS 0
NCT02964559 Phase II Pembrolizumab Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer Completed USA 0
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Active, not recruiting USA 0
NCT03108131 Phase II Atezolizumab + Cobimetinib Cobimetinib and Atezolizumab in Advanced Rare Tumors Completed USA 0
NCT03212404 Phase I Cosibelimab Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Recruiting POL | NZL | FRA | ESP | AUS 4
NCT03284424 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629) Completed USA | NOR | ISR | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT03524326 Phase I Cetuximab + Lenvatinib Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma Completed USA 0
NCT03539198 Phase 0 Nivolumab Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer Terminated USA 0
NCT03666325 Phase II Pembrolizumab Cetuximab + Pembrolizumab Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance (I-Tackle) Unknown status ITA 0
NCT03767348 Phase Ib/II Nivolumab + RP1 RP1 Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Recruiting USA | GBR | FRA | ESP | DEU 0
NCT03816332 Phase I Ipilimumab + Nivolumab + Prednisone + Tacrolimus Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Active, not recruiting USA 0
NCT03833167 Phase III Pembrolizumab Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) Active, not recruiting USA | ROU | POL | NZL | NOR | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG 6
NCT03871348 Phase I SAR441000 Cemiplimab + SAR441000 A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors Terminated USA | NLD | FRA | ESP | DEU | BEL 0
NCT03889912 Phase I Cemiplimab Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT03894618 Phase I SL-279252 SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Completed USA | ESP | CAN | BEL 0
NCT03901573 Phase Ib/II Atezolizumab + NT-I7 High-Risk Skin Cancers With Atezolizumab Plus NT-I7 Terminated USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03944941 Phase II Avelumab Avelumab + Cetuximab Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Active, not recruiting USA 0
NCT03969004 Phase III Cemiplimab Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Active, not recruiting USA | POL | NZL | ITA | IRL | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS 2
NCT04050436 Phase II Cemiplimab + RP1 RP1 Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS) Active, not recruiting USA | POL | ITA | GRC | FRA | ESP | DEU | CAN | BGR | AUS 0
NCT04105543 Phase I CLR 131 CLR 131 Combined With Radiation for Head and Neck Cancer Completed USA 0
NCT04154943 Phase II Cemiplimab Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma Active, not recruiting USA | DEU | AUS 0
NCT04160065 Phase I IFx-Hu2.0 Immunotherapy With IFx-Hu2.0 Vaccine for Advanced MCC or cSCC Completed USA 0
NCT04163952 Phase I Panitumumab + Talimogene laherparepvec Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Active, not recruiting USA 0
NCT04204837 Phase II Nivolumab + Relatlimab Nivolumab Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin Recruiting AUT 0
NCT04260802 Phase Ib/II OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Recruiting CAN 0
NCT04293679 Phase Ib/II Cotsiranib Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC Completed USA 0
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04305795 Phase Ib/II ASP-1929 + Pembrolizumab ASP-1929 + Cemiplimab An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors Active, not recruiting USA 0
NCT04315701 Phase II Cemiplimab A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer Recruiting USA 0
NCT04339062 Phase I Cemiplimab Cemiplimab + Everolimus + Prednisone Cemiplimab + Prednisone + Sirolimus Cemiplimab in AlloSCT/SOT Recipients With CSCC (CONTRAC) Active, not recruiting USA 0
NCT04389632 Phase I SGN-B6A A Study of SGN-B6A in Advanced Solid Tumors Recruiting USA | GBR | FRA | ESP | CHE 1
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04428671 Phase I Cemiplimab Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer Recruiting USA 0
NCT04450901 Phase I YBL-006 Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors Active, not recruiting AUS 2
NCT04502888 Phase I SL-172154 Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Terminated USA 0
NCT04521413 Phase Ib/II CFI-402411 + Pembrolizumab CFI-402411 Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies Recruiting USA | CAN 1
NCT04521621 Phase Ib/II Coxsackievirus A21 + Pembrolizumab A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) Terminated USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN 4
NCT04620200 Phase II Ipilimumab + Nivolumab Nivolumab Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE) Unknown status NLD 0
NCT04632433 Phase II Cemiplimab Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma Active, not recruiting ITA 0
NCT04710498 Phase II Atezolizumab Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma Active, not recruiting USA 0
NCT04717375 Phase Ib/II BND-22 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Recruiting USA | ISR | GBR | CAN 0
NCT04787042 Phase Ib/II Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 Active, not recruiting USA 0
NCT04807777 Phase II Ruxolitinib Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Active, not recruiting USA 0
NCT04808999 Phase II Pembrolizumab Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) Active, not recruiting USA 0
NCT04819373 Phase II BDB001 BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors Completed USA 0
NCT04913220 Phase Ib/II Cemiplimab + THOR-707 A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers Active, not recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT04916002 Phase II Cemiplimab + Vidutolimod CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer Terminated USA | AUS 0
NCT04925713 Phase I IFx-Hu2.0 IFx-Hu2.0 for the Treatment of Patients With Skin Cancer Completed USA 0
NCT04958239 Phase I BI 765179 + Ezabenlimab BI 765179 A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer Recruiting USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS 4
NCT04975152 Phase I Cemiplimab Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT04985825 Phase II Imgatuzumab Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE) Withdrawn 0
NCT05025813 Phase II Pembrolizumab Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma (DESQUAMATE) Recruiting AUS 0
NCT05043714 Phase I NG-641 + Nivolumab Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA) Active, not recruiting USA | GBR 0
NCT05069935 Phase I Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Terminated USA 0
NCT05070403 Phase II Afatinib Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT05076760 Phase I MEM-288 Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) Recruiting USA 0
NCT05085496 Phase I Atezolizumab Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous Squamous Cell Carcinoma Recruiting USA 0
NCT05086692 Phase Ib/II MDNA11 + Pembrolizumab A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) Recruiting USA | CAN | AUS 1
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05220748 Phase I Pembrolizumab + RM-1995 RM-1995 RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC Withdrawn 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | POL | ITA | HUN | FRA | ESP | CZE | BEL 1
NCT05269381 Phase I Cyclophosphamide + Neoantigen peptide vaccine + Pembrolizumab + Sargramostim Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA) Recruiting USA 0
NCT05329792 Phase II Daromun L19IL2/L19TNF in Skin Cancer Patients Recruiting ITA | FRA | ESP 0
NCT05565417 Phase Ib/II IMT-009 Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05574101 Phase II Cemiplimab A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Recruiting USA 0
NCT05620134 Phase Ib/II JK08 A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer Active, not recruiting ESP | BEL 0
NCT05714553 Phase Ib/II Docetaxel + Leucovorin + NUC-3373 Leucovorin + NUC-3373 + Pembrolizumab NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Recruiting GBR 0
NCT05729139 Phase I Cemiplimab + Peg-interferon alfa-2a Cemiplimab/Peg-Interferon-a in Advanced CSCC Withdrawn USA 0
NCT05821777 Phase Ib/II LB101 A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors Recruiting USA | FRA 0
NCT05858229 Phase Ib/II RP1 Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. Recruiting USA 0
NCT05859074 Phase I MQ710 + Pembrolizumab MQ710 A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Active, not recruiting USA 0
NCT05878288 Phase II Cemiplimab Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN) Active, not recruiting AUS 0
NCT05888844 Phase II INCB099280 A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Active, not recruiting TUR | ROU | NZL | HUN | HRV | FRA | ESP | CAN | BRA | AUS 5
NCT05896839 Phase Ib/II Ipilimumab + Nivolumab + Prednisone + Sirolimus Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Recruiting USA 0
NCT05904496 Phase I BGB-30813 BGB-30813 + Tislelizumab A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting USA | ESP | AUS 0
NCT05938296 Phase I oHSV2-PD-L1/CD3-BsAb oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection Recruiting USA 0
NCT06014086 Phase I PH-762 Intratumoral PH-762 for Cutaneous Carcinoma Recruiting USA 0
NCT06036836 Phase II Lenvatinib + Pembrolizumab Lenvatinib + MK-4280A MK-4280A Pembrolizumab Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Recruiting USA | TUR | NLD | ITA | FRA | DEU | CAN | AUS 2
NCT06090266 Phase Ib/II Cemiplimab + OR502 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Recruiting USA 0
NCT06295809 Phase II Pembrolizumab mRNA-4157 + Pembrolizumab A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) Recruiting USA | ROU | POL | NZL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 2
NCT06331598 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) Recruiting ESP 0
NCT06514651 Phase I MAQ-001 Ipilimumab + MAQ-001 MAQ-001 in Patients With Advanced Solid Tumors Recruiting FRA 0
NCT06567314 Phase II Ivonescimab Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma Not yet recruiting USA 0
NCT06580054 Phase II Pembrolizumab Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma Not yet recruiting USA 0